The concurrent targeting of Gli1 and Akt pathways represents a rational and promising strategy to overcome intrinsic or acquired resistance associated with Hedgehog inhibition, particularly in leukemias characterized by non-canonical Hedgehog activation [20,30,48,49]. The gene discussed is GLI1; the disease is leukemia.